Editorial: thiopurines in the multidrug era—time to rescue our memories over half a century of experience. Authors' reply

Ardabili, Ashkan Rezazadeh; Mujagic, Zlatan; Oostenbrug, Liekele E.; Romberg‐Camps, Mariëlle; Jonkers, Daisy; Bodegraven, Adriaan A. van; Pierik, Marieke

doi:10.1111/apt.17186

Search citation statements

Order By: Relevance

Paper Sections

Select...

Tg Versus Conventional Thiopurine Derivatives (Aza/mp)1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In early studies, cases of nodular regenerative hyperplasia (NRH) of the liver (which may result in non-cirrhotic portal hypertension) were observed during TG therapy 46. However, in later studies, it was concluded that this was likely to be a dose-related adverse event 29 47–49. Furthermore, NRH was also seen in patients using other thiopurine derivatives (AZA/MP) and was potentially reversible after cessation of therapy, leading to a very mild disease course 47 50 51.…”

Section: Tg Versus Conventional Thiopurine Derivatives (Aza/mp)mentioning

confidence: 99%

Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease

Boer

Simsek

Meijer

et al. 2023

Gut

View full text Add to dashboard Cite

Drug rediscovery refers to the principle of using ‘old’ drugs outside the indications mentioned in the summary of product characteristics. In the past decades, several drugs were rediscovered in a wide variety of medical fields. One of the most recent examples is the unconditional registration of thioguanine (TG), a thiopurine derivative, in patients with inflammatory bowel disease in the Netherlands. In this paper, we aim to visualise potential hurdles that hamper drug rediscovery in general, emphasise the global need for optimal use and development of potentially useful drugs, and provide an overview of the registration process for TG in the Netherlands. With this summary, we aim to guide drug rediscovery trajectories in the near future.

show abstract

Section: Tg Versus Conventional Thiopurine Derivatives (Aza/mp)mentioning

confidence: 99%

Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease

Boer

Simsek

Meijer

et al. 2023

Gut

View full text Add to dashboard Cite

show abstract

Editorial: thiopurines in the multidrug era—time to rescue our memories over half a century of experience. Authors' reply

Abstract: LINKED CONTENT This article is linked to Rezazadeh Ardabili et al papers. To view these articles, visit https://doi.org/10.1111/apt.17128 and https://doi.org/10.1111/apt.17164

Cited by 1 publication

References 10 publications

Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease

Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease

Contact Info

Product

Resources

About